Lexicon Pharma (LXRX)
2.24
-0.02 (0.88%)
Upcoming Events
Latest Headlines
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
September 1, 2026 4:05 PM - StreetInsider
Lexicon sotagliflozin shows consistent results across blood pressure levels
August 31, 2026 8:32 AM - StreetInsider
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
August 31, 2026 8:30 AM - StreetInsider
Lexicon earns third $10M milestone from Novo Nordisk for LX9851
August 24, 2026 8:30 AM - StreetInsider
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
August 24, 2026 8:30 AM - StreetInsider
Form EFFECT LEXICON PHARMACEUTICALS,
August 17, 2026 6:15 AM - SEC Filing
Form S-3 LEXICON PHARMACEUTICALS,
August 6, 2026 5:07 PM - SEC Filing
Form S-8 LEXICON PHARMACEUTICALS,
August 6, 2026 4:38 PM - SEC Filing
Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30
August 6, 2026 4:08 PM - SEC Filing
Form SCHEDULE 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC
August 6, 2026 10:31 AM - SEC Filing
Lexicon Pharma (LXRX) Misses Q2 EPS by 2c
August 6, 2026 7:50 AM - StreetInsider
Form 8-K LEXICON PHARMACEUTICALS, For: Aug 06
August 6, 2026 7:33 AM - SEC Filing
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 6, 2026 7:30 AM - StreetInsider
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026 8:30 AM - StreetInsider
Lexicon completes enrollment in Phase 3 HCM trial of sotagliflozin
July 27, 2026 8:30 AM - StreetInsider
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
July 27, 2026 8:30 AM - StreetInsider
Full Article List
